.Attributes Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of patients with HER2+ enhanced breast cancer as well as active or dependable human brain metastases presented constant intracranial activity and also wide spread efficacy of T-DXd.